Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: jmt who wrote (3316)	7/17/1998 6:45:00 PM
From: Hyrulean King	Respond to of 5402

BZZZZZZ. that is incorrect. i'll take Shill Morons for $500 Alex.

To: jmt who wrote (3316)	7/17/1998 7:06:00 PM
From: R>G>	Read Replies (1) \| Respond to of 5402

JMT Can you clarify your statement? But he has not engineered this product. He is simply marketing a product which has been tested and rejected in the past. 1. Difference between first generation and second generation drug. Both drugs use an emulsion. In Japan's version 1st generation drug they used 2 flurocarbons, 8 adjuvent solutions, and 2 surfactants. Sanguine's 2nd generation drug uses 1 flurocarbon and 1 surfactant. This version is a much cleaner product. Another very important thing to remember is that with this being a 2nd generation drug the time frame for approval should be much shorter. It took about 10 years when Dr. Drees was head of Alpha ( US subsidiary of Green Cross) to get FDA approval. Now that the 1st generation drug has been tested on approximately 13,000 people and saved lives, the process should be quicker, cheaper, and smoother. He is hoping for FDA approval in 3 years. This is not the same product!!!!!!!! 2. You say this product was rejected in the past. I am not familiar with it ever being rejected. Can you clarify?? 3. This product is being worked on as we speak. There are about 9 variations of this product that are being worked on. There is about a 80/20% ratio for this product, what they are working on now is slightly changing the ratio to find the best one, say 83/17 %or 78/22%,etc etc.

To: jmt who wrote (3316)	7/17/1998 7:21:00 PM
From: Janice Shell	Read Replies (1) \| Respond to of 5402

For me, this raises some questions as well: NOTE #13 - Employment Agreement The Company has employment agreements with Dr. Thomas Drees and Anthony G. Hargreaves dated January 22, 1990. The agreements call for a base salary of $120,000 to Dr. Drees and $72,000 to Mr. Hargreaves annually. Insurance benefits, home office reimbursement, and an automobile are to be provided by the Company and reimbursement for out of pocket expenses will be paid to Dr. Drees and Anthony G. Hargreaves. Subject to an agreement of June 2, 1994, Dr. Drees and Mr. Hargreaves agreed to cancel all outstanding accruals for expenses under the provision of the Agreements and to accept as full satisfaction of all of their claims against Sanguine Corporation the payments they received in November 1993. In addition the Agreements were modified to provide that for June, July, and August of 1994, salary shall be paid at one fourth the amount specified by the Agreements. Commencing September 1, 1994, Dr. Drees and Mr. Hargreaves will be entitled to receive one half the salary specified until such time as Sanguine Corporation shall have raised $1,500,000 in debt or equity funding. All funds raised since the completion of the Agreement and Plan of Reorganization between Sanguine Corporation (California), and Sanguine Corporation (Nevada), are being counted in arriving at this sum. If Drees is an internationally recognized authority on this stuff, why doesn't he go to work for someone who can pay him what he deserves? Form 10KSB for SANGUINE CORP filed on Apr 15 1998 www4.edgar-online.com